- Insider Monkey•2 days ago
Although the broader markets are still down/flat due in large part to Apple Inc. (NASDAQ:AAPL)’s disappointing earnings report, the indexes have nevertheless made a comeback of sorts as the latest EIA numbers of a drop of 0.6 million barrels gave a boost to energy related names. Among the other securities that are also capturing investors’ attention […]
- TheStreet.com•2 days ago
More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
- Business Wire•2 days agoARIAD Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research
ARIAD Pharmaceuticals, Inc. today announced the publication of preclinical data on brigatinib, its investigational oral tyrosine kinase inhibitor in development for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer .
Ariad Pharmaceuticals Inc. (ARIA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||8.86 - 9.45|
|52wk Range||4.37 - 14.34|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-28.65|
|Avg Vol (3m)||6,799,112|
|Dividend & Yield||N/A (N/A)|